Organization Description
Mitrix Bio is a Palo Alto-based clinical-stage biotech startup developing mitochondrial transplantation to replace aging mitchondria in our cells, restore organ function, and spur rejuvenation. Mitrix’s specific approach is what they term “Mitlets:” bioreactor-expanded mitochondria delivered in platelet-derived extracellular vesicles. Dr. Eric Boilard and colleagues at Université Laval in Quebec discovered that when platelets are activated pro-thrombotic stimuli or reach the end of their lifespan, they release their mitochondria, both as free organelles and encapsulated in extracellular vesicles i.e., “mitlets.” While cells are capable of taking up “naked” mitochondria, mitlets appear to penetrate host cells more efficiently. Additionally, Mitrix’s research has shown that mitochondria originating in ten or more donors can be pooled to deliver very high numbers of the organelle to patients without evidence of risk.
In July 2025, Mitrix announced that they intended to dose their first human subject August 1, and intend to dose more, for a total of ten. The study is open label and subjects must self-finance, so it is not a trial in the conventional sense. Their first subject will be 90 year-old University of Washington Emeritus Professor of Physics John G. Cramer.
Mitrix is also working on an experimental biological age test for mitochondria called “MitoClock.”
Team
